Algert Global LLC Crinetics Pharmaceuticals, Inc. Transaction History
Algert Global LLC
- $4.25 Billion
- Q4 2024
A detailed history of Algert Global LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Algert Global LLC holds 28,777 shares of CRNX stock, worth $990,504. This represents 0.03% of its overall portfolio holdings.
Number of Shares
28,777
Previous 42,777
32.73%
Holding current value
$990,504
Previous $2.19 Million
32.71%
% of portfolio
0.03%
Previous 0.06%
Shares
9 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$313 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$239 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$214 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$211 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$186 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.85B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...